Clinical trial / 2018
Short-term fasting during chemotherapy was well tolerated and reduced quality of life deterioration.
In this randomized crossover pilot trial with 34 patients undergoing chemotherapy for gynecological cancer, 60-hour fasting (36 hours before to 24 hours after treatment) was compared to a normocaloric diet. Fasting reduced chemotherapy-related declines in quality of life to below the minimally important difference. Deterioration of total FACIT-F scores was lower during fasted cycles compared to non-fasted cycles in both groups without serious adverse events.
- Study type
- Randomized crossover trial
- Who was studied
- 34 patients with gynecological cancer undergoing chemotherapy
- What was measured
- Quality of life and fatigue during chemotherapy
THE PAPER
The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study.
Bauersfeld SP, Kessler CS, Wischnewsky M, Jaensch A, Steckhan N, Stange R, Kunz B, Brückner B, Sehouli J, Michalsen A. BMC Cancer, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.